Identify Genes/Pathways Responsible for Progression From Low Risk to Higher Risk Prostate Cancer
Recruiting · NCT03789253 · Observational (researchers observe without assigning treatment) · Lead sponsor: National Taiwan University Hospital
View the official record on ClinicalTrials.gov →What this trial is about
In Taiwan, about 70% of new incident prostate cancer patients have localized disease. Most patients were detected by PSA screening. Among them, many had low-risk PC, which is very likely latent in nature, progresses slowly, and rarely leads to death. Most patients died of other causes, such as other cancers, cardiovascular diseases, and diabetes mellitus. Many guidelines recommend that active surveillance (AS) or watchful waiting (WW) is a good option for low risk patients to avoid overtreatment-related complications. However, 30% of patients on AS will finally need definitive treatments due to disease progression within 10 years. We hypothesize that there are differential gene expressions between progressive and non-progressive tumors. If we can identify key genes or pathways that are responsible for progression of low risk PC to higher risk diseases, PC progression could be reduced substantially by regulating these genes or pathways and maintain long-term cancer latency to control non-metastatic PC. In light of the high prevalence rate of latent PC in adult men, the strategy is in fact the best strategy for preventing clinical PC.
Who can take part
Inclusion criteria
- Historically or cytologically confirmed adenocarcinoma of prostate.
- Have or ever received active Surveillance as the main conservative management at NTUH (National Taiwan University Hospital).
- Have or will receive prostate biopsy to confirm tumor progression after the diagnosis of prostate cancer.
Exclusion criteria
- Have received systemic chemotherapy, pelvic radiotherapy or androgen deprivation therapy (ADT) before the obtainment of pathological specimen from prostate operation or biopsy.
- Subjects who disagree with signing the informed consent.
Where it is running
1 location listed.
- National Taiwan University - Taipei, Taiwan